Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
Completed
- Conditions
- Hypertension
- Interventions
- Registration Number
- NCT02242383
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13248
Inclusion Criteria
- Age ≥ 18 years, insufficiently treated hypertension
Exclusion Criteria
- Age < 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Essential hypertension Telmisartan - Essential hypertension Telmisartan in combination with hydrochlorothiazide -
- Primary Outcome Measures
Name Time Method Changes in morning heart rate Pre-dose, up to 6 months after start of treatment Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP Pre-dose, up to 6 months after start of treatment Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale Up to 6 months after start of treatment Changes in morning blood pressure (BP) Pre-dose, up to 6 months after start of treatment Changes in metabolic laboratory parameters Pre-dose, up to 6 months after start of treatment Investigator assessment of effects on metabolism on a 3-point rating scale Up to 6 months after start of treatment Investigator assessment of tolerability on a 5-point rating scale Up to 6 months after start of treatment Number of patients with adverse events Up to 6 months
- Secondary Outcome Measures
Name Time Method